The FDA has approved an autoinjector formulation of Zilbrysq, a complement inhibitor for the treatment of generalized myasthenia gravis.

While the national burden of pediatric-onset multiple sclerosis is stable, regional incidence and disability rates are increasing in some states.

Starting disease-modifying therapy within 90 days of a neuromyelitis optica spectrum disorder attack may improve long-term disability recovery.